首页> 外文期刊>BMC Infectious Diseases >The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series
【24h】

The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series

机译:结肠内万古霉素治疗严重艰难梭菌结肠炎的疗效:系列病例

获取原文
           

摘要

Background Clostridium difficile infection (CDI) unresponsive to the standard treatments of metronidazole and oral vancomycin requires aggressive medical management and possible surgical intervention including colectomy. Intracolonic vancomycin therapy has been reported to be particularly promising in the setting of severe CDI in the presence of ileus. This is a descriptive case series exploring the effect of adjunctive intracolonic vancomycin therapy on the morbidity and mortality in patients with moderate to severe CDI. Methods A retrospective chart review was conducted on 696 patients with CDI seen at a single institution. Each patient was assigned a severity score and 127 patients with moderate to severe CDI were identified. We describe the clinical presentation, risk factors and hospital course comparing those that received adjunctive intracolonic vancomycin to those that only received standard therapy. Results The group that received adjunctive intracolonic vancomycin had higher rates of toxic megacolon, intensive care unit (ICU) admission, and colectomy, and yet maintained a similar mortality rate as the group that received only standard treatment. Conclusion The intracolonic vancomycin group experienced more complications but showed a similar mortality rate to the standard therapy group, suggesting that intracolonic vancomycin may impart a protective effect. This study adds further evidence for the need of a randomized controlled study using intracolonic vancomycin as adjunctive therapy in patients presenting with severe CDI.
机译:背景技术对甲硝唑和口服万古霉素的标准治疗无反应的艰难梭菌感染(CDI)需要积极的医学管理和可能的手术干预,包括结肠切除术。据报道,在存在肠梗阻的情况下,在严重CDI的情况下,结肠内万古霉素疗法特别有希望。这是一个描述性病例系列,探讨辅助结肠内结肠万古霉素治疗对中度至重度CDI患者的发病率和死亡率的影响。方法回顾性分析了696例CDI患者的病历。为每位患者分配了严重程度评分,并鉴定出127位中度至重度CDI患者。我们描述了临床表现,危险因素和医院病历,将接受辅助结肠内结肠万古霉素治疗的患者与仅接受标准疗法的患者进行了比较。结果接受辅助结肠内结肠万古霉素治疗的组中毒性巨结肠,重症监护病房(ICU)入院和结肠切除术的发生率更高,但死亡率仍与仅接受标准治疗的组相似。结论结肠内万古霉素组并发症多,但死亡率与标准治疗组相似,提示结肠内万古霉素可能具有保护作用。这项研究为有严重CDI的患者需要使用结肠内万古霉素作为辅助治疗的随机对照研究提供了更多证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号